BrunoSan Finance Intelligence · May 30, 2026

Finance Intelligence News

Every article includes an Intel Score breakdown — so you know exactly how strong each signal is and where it came from. Not editorial judgment. Signal mathematics.

🏦 RATE DECISION
1.000

Fed Governor Bowman Signals High Bar for Rate Hikes, Citing Ineffective Policy Against Supply-Side Inflation

Federal Reserve Governor Michelle Bowman argued against further interest rate hikes, stating that monetary policy is ill-equipped to counter current supply-side inflation, a stance that challenges market pricing for tightening as the 10Y-2Y spread holds at -15 bps.
⚡ Score 1.000 🌐 1 source 📅 May 30, 2026 Read Analysis →
📊 EARNINGS
1.000

SentinelOne Slashes Full-Year Guidance; Stock Drops 8% on AI Pivot and Layoffs

SentinelOne (NYSE: S) stock dropped 8% in after-hours trading despite a Q1 earnings beat, as the company slashed its full-year 2027 revenue guidance to $920 million and announced a 5% workforce reduction to accelerate its investment in AI-native security platforms.
⚡ Score 1.000 🌐 1 source 📅 May 30, 2026 Read Analysis →
🏦 RATE DECISION
1.000

Wall Street's Rate Path Anxiety Intensifies as Jobs Data Looms Over Equity Rally

The U.S. equity rally confronts a decisive moment with the upcoming jobs report, a key input that will shape the Federal Reserve's restrictive policy path. Market positioning is acutely sensitive to a deviation from expectations, with rising bond yields signaling a disconnect between credit and equity risk assessments.
⚡ Score 1.000 🌐 1 source 📅 May 30, 2026 Read Analysis →
🚀 IPO
1.000

HWH International Discloses Nasdaq Non-Compliance Notice Over Delayed 10-K Filing

HWH International Inc. has received a formal notice of non-compliance from the Nasdaq Stock Market for failing to file its Form 10-K for the fiscal year ended December 31, 2025, a direct violation of exchange listing rules that jeopardizes its market status.
⚡ Score 1.000 🌐 1 source 📅 May 30, 2026 Read Analysis →
🚀 IPO
1.000

Actinium Pharmaceuticals Faces NYSE Delisting After Failing Continued Listing Standards

Actinium Pharmaceuticals received a formal notice of non-compliance from the NYSE American exchange for its stock trading at a persistently low price, a violation of Section 1003(f)(v) of the exchange's guide. The notice, disclosed in a May 29, 2026 SEC filing, initiates a cure period where the company must present a viable plan to regain compliance or face delisting to an OTC market.
⚡ Score 1.000 🌐 1 source 📅 May 30, 2026 Read Analysis →